The Max 3 syringe-less injector reportedly offers improved efficiency and intuitive features with contrast media use for magnetic resonance imaging.
The Food and Drug Administration has granted 510(k) clearance for the Max 3™ contrast media injector for use in magnetic resonance imaging (MRI) exams.
Offering ease of use features to foster workflow efficiencies, the Max 3 is a syringe-less injector, according to Bracco Diagnostics, the manufacturer of the modality, which was developed in collaboration with Ulrich Medical.
Emphasizing direct injection from original contrast media vials, Bracco Diagnostics highlighted the Max 3’s combination of the Easy-Click Cassette flex and SafeConnect. The company noted these features enable dedicated connection to patient tubing with protection from retrograde contamination. The connector with the Easy-Click Cassette can be utilized within a 24-hour period or up to a maximum of 96 bottles of contrast media, whichever occurs first, according to Bracco Diagnostics.
The company pointed out that the lack of power cables with Max 3 enable convenient positioning of the device within the MRI room. In addition to eliminating the need to refill syringes, Bracco Diagnostics said use of the Max 3 reduces disposable plastic waste.
"We're thrilled to bring an intuitive, easy-to-use, and environmentally friendly solution to the radiology community in collaboration with Bracco," said Klaus Kiesel, the chief executive officer of Ulrich Medical. "Together, we're taking MRI innovation to the next level in health care."
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.